Abstract
GL331 is a novel podophyllotoxin-derived compound and is more efficacious than its congener VP-16 in killing several types of cancer cells, that has promoted considerable interest in its possibility of clinical use. In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated. We found that GL331-induced cell cycle perturbation occurred upon initial 8-h exposure, and pretreatment of NPC-TW01 cells with GL331 for 8 h significantly interfered with the cytotoxicities of VP-16, cisplatin, 5-fluorouracil and adriamycin. When the schedule of drug administration was reversed, high-toxic concentrations of these agents revealed an antagonistic effect on GL331; however, their low-toxic doses had the additive or even more-than-additive effect on the cytotoxicity induced by GL331 at 0.1 μM or less, but for GL331 concentrations of greater than 1 μM, the effect became less than additive. These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents.
Similar content being viewed by others
References
Whang-Peng J, HuangT-S.Newtrials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J Intern Med 84.
Huang T-S, Shu C-H, Shih Y-L, et al. J. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett 1996; 110: 77–85.
Huang T-S, Lee C-C, Chao Y, et al. A novel podophyllotoxinderived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceut Res 1999; 16: 997–1002.
Kuo M-L, Shen S-C, Yang C-H, Chuang S-E, Cheng A-L, Huang T-S. Bcl-2 prevents topoisomerase II inhibitor GL331–induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. Oncogene 1998; 17: 2225–2234.
Huang T-S, Yang WK, Whang-Peng J. GL331–induced disruption of cyclin B1/CDC 2 complex and inhibition of CDC 2 kinase activity. Apoptosis 1996; 1: 213–217.
Huang T-S, Shu C-H, Yang WK, Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331–induced apoptosis. Cancer Res 1997; 57: 2974–2978.
Sullivan DM, Chow K-C, Ross WE. Topoisomerase II mediated mechanisms of drug resistance. In: Kessel D, ed. Resistance to Antineoplastic Drugs. Boca Raton, FL: CRC Press, 1989: 281–292.
Lin C-T, Chan W-Y, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993; 68: 716–727.
Shu C-H, Yang WK, Huang T-S. Increased cyclin B1/CDC 2 kinase activity and phosphorylation of Bcl-2 associated with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 1996; 1: 141–146.
Overbeeke R, Steffens-Nakken H, Vermes I, Reutelingsperger C, Haanen C. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 1998; 3: 115–121.
Huang T-S, Kuo M-L, Shew J-Y, Chou Y-W, Yang WK. Distinct p53–mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNAdamaging agents. Oncogene 1996; 13: 625–632.
Friedland ML. Combination chemotherapy. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins, 1992: 90–95.
Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. Choice of drugs for cancer chemotherapy. In: The Anticancer Drugs. New York: Oxford University Press, 1994: 235–246.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, TS., Shu, CH., Lee, CC. et al. In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents. Apoptosis 5, 79–85 (2000). https://doi.org/10.1023/A:1009693811093
Issue Date:
DOI: https://doi.org/10.1023/A:1009693811093